76.22
+6.32(+9.04%)
Currency In USD
| Previous Close | 69.9 |
| Open | 67.68 |
| Day High | 76.52 |
| Day Low | 66.58 |
| 52-Week High | 76.76 |
| 52-Week Low | 11.17 |
| Volume | 204,927 |
| Average Volume | 175,006 |
| Market Cap | 842.97M |
| PE | -30.13 |
| EPS | -2.53 |
| Moving Average 50 Days | 55.19 |
| Moving Average 200 Days | 30.73 |
| Change | 6.32 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $4,483.53 as of October 14, 2025 at a share price of $76.22. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 0 years ago, it would be worth $4,483.53 as of October 14, 2025 at a share price of $76.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up to $2.6 million in non-dilutive funding anticipated over the grant period Top-line data from SELVA expe
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
GlobeNewswire Inc.
Sep 24, 2025 10:00 AM GMT
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
GlobeNewswire Inc.
Sep 17, 2025 11:30 AM GMT
Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systema